Founded Spin-Offs

This year, the Pre-GoBio program is supporting two planned spin-offs. Paul Schöpe aims to bring a drug targeting colorectal cancer metastases to market. And Ines Lahmann will further develop NMJCare, a model that can be used to test therapies for neuromuscular diseases. 

Researchers at the Max Delbrück Center have developed a fast, cost-effective blood-based tool that can identify and classify immune deficiencies with high accuracy. The approach, published in ​“Nature Communications,” could help address long-standing gaps in diagnosing immune disorders. 

Discovery, invention and spin-offs – Nevine Shalaby, Head of Innovation & Entrepreneurship was interviewed by ​“Buch Inside” about the path from research to innovation. She discusses how her team supports marketable research discoveries made at the Max Delbrück Center. 

During the Predictive Systems Medicine Partnering Event at the Max Delbrück Center, researchers and industry representatives shared insights and explored commercialization opportunities – advancing our mission to turn discovery into real-world health impact.